loadpatents
Patent applications and USPTO patent grants for Zhou; Xiao Xiong.The latest application filed is for "novel 1,3-oxazolidine compounds and their use as renin inhibitors".
Patent | Date |
---|---|
Novel 1,3-oxazolidine Compounds And Their Use As Renin Inhibitors App 20130005730 - Sun; Piaoyang ;   et al. | 2013-01-03 |
Novel 3'-deoxy-3'-methylidene-beta-l-nucleosides App 20120309705 - Zhou; Xiao Xiong ;   et al. | 2012-12-06 |
Acyclic Nucleoside Derivatives App 20120123119 - ENGELHARDT; Per ;   et al. | 2012-05-17 |
1-[2', 3' -dideoxy-3' C- (hydroxymethyl)--beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors Grant 8,143,396 - Zhou , et al. March 27, 2 | 2012-03-27 |
Acyclic nucleoside derivatives Grant 8,124,609 - Engelhardt , et al. February 28, 2 | 2012-02-28 |
1-[2', 3' -dideoxy-3' C- (hydroxymethyl) - Beta-d-erythro-pentofuranosyl] Cytosine Derivatives As Hiv Inhibitors App 20110112294 - ZHOU; Xiao-Xiong ;   et al. | 2011-05-12 |
Cysteine Protease Inhibitors App 20110112089 - NILSSON; Magnus ;   et al. | 2011-05-12 |
Cysteine protease inhibitors Grant 7,915,300 - Nilsson , et al. March 29, 2 | 2011-03-29 |
1-[2',3' -dideoxy-3' C-(hydroxymethyl)--beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV Grant 7,888,367 - Zhou , et al. February 15, 2 | 2011-02-15 |
Compounds useful in the treatment of HIV Grant 7,829,548 - Zhou , et al. November 9, 2 | 2010-11-09 |
Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine Grant 7,825,238 - Zhou , et al. November 2, 2 | 2010-11-02 |
Acyclic Nucleoside Derivatives App 20090076041 - ENGELHARDT; Per ;   et al. | 2009-03-19 |
Acyclic nucleoside derivatives Grant 7,432,274 - Engelhardt , et al. October 7, 2 | 2008-10-07 |
Cysteine Protease inhibitors App 20080234260 - Nilsson; Magnus ;   et al. | 2008-09-25 |
1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv App 20080221140 - Zhou; Xiao-Xiong ;   et al. | 2008-09-11 |
Compounds Useful in the Treatment of Hiv App 20080176817 - Zhou; Xiao-Xiong ;   et al. | 2008-07-24 |
Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine Grant 7,071,173 - Zhou , et al. July 4, 2 | 2006-07-04 |
Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine App 20060122383 - Zhou; Xiao-Xiong ;   et al. | 2006-06-08 |
Antiviral Methods Employing Double Esters Of 2', 3'-dideoxy-3'-fluoroguanosine App 20060058259 - Zhou; Xiao-Xiong ;   et al. | 2006-03-16 |
Treatment of viral infections using prodrugs of 2',3-dideoxy,3'-fluoroguanosine Grant 6,974,802 - Zhou , et al. December 13, 2 | 2005-12-13 |
Acyclic nucleoside derivatives App 20040132749 - Engelhardt, Per ;   et al. | 2004-07-08 |
Acyclic nucleoside derivatives Grant 6,703,394 - Engelhardt , et al. March 9, 2 | 2004-03-09 |
Prodrugs App 20030186924 - Zhou, Xiao-Xiong ;   et al. | 2003-10-02 |
Acyclic nucleoside derivatives App 20020188125 - Engelhardt, Per ;   et al. | 2002-12-12 |
Non-nucleoside reverse transcriptase inhibitors App 20020128301 - Zhou, Xiao-Xiong ;   et al. | 2002-09-12 |
Acyclic nucleoside derivatives Grant 5,869,493 - Engelhardt , et al. February 9, 1 | 1999-02-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.